MedTrace Logo

Prevention of Postoperative Delirium With Donepezil

NCT00220896 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2011-09-14

No results posted yet for this study

Summary

Patients undergoing hip or knee joint replacement at the age of 70 years or above who are cognitively unimpaired will receive donepezil or matching placebo before (over 5-7 days), during and after (over 7 days) surgery. The incidence of delirium will be monitored at 3 days, 7 days, and 49 days following surgery. We hypothesize that the incidence of delirium can be lowered from 20 per cent to 10 per cent by the intervention.

Conditions

  • Cognitively Normal Elderly Individuals

Interventions

DRUG

Donepezil

Sponsors & Collaborators

  • Eisai Deutschland

    collaborator OTHER

  • Technical University of Munich

    lead OTHER

Principal Investigators

  • Janine Diehl, M. D. · Dept. of Psychiatry, Technische Universitaet Muenchen

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Completion
2009-03-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00220896 on ClinicalTrials.gov